Market capitalization | €4.89b |
P/E (TTM) P/E ratio | 27.39 |
P/S ratio (TTM) P/S ratio | 4.13 |
P/B ratio (TTM) P/B ratio | 3.03 |
Dividend yield | 1.31% |
Last dividend (FY24) | €1.20 |
Revenue growth (TTM) Revenue growth | 3.20% |
Revenue (TTM) Revenue | €1.19b |
EBIT (operating result TTM) EBIT | €272.94m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
16 Analysts have issued a DiaSorin S.p.A. forecast:
16 Analysts have issued a DiaSorin S.p.A. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 1,185 1,185 |
3%
3%
|
|
Gross Profit | 818 818 |
19%
19%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | 273 273 |
16%
16%
|
Net Profit | 188 188 |
17%
17%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
DiaSorin SpA engages in the development, production, and marketing of reagent kits for in vitro diagnostics. It specializes in the provision of immunodiagnostics and molecular diagnostics solutions which meet the needs of the following clinical areas: infectious diseases, cardiac markers, bone metabolism, hepatitis & retrovirus, oncology and endocrinology. The company was founded in 1968 and is headquartered in Vercelli, Italy.
Head office | Italy |
CEO | Carlo Rosa |
Founded | 1968 |
Website | www.diasorin.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.